Patent Grant
10117977
The present invention relates generally to wound therapy devices, including reduced pressure therapy devices and the suction applied by reduced pressure therapy devices.
Medical practice commonly uses suction devices to improve drainage of fluids from the body of a patient. For example, suction devices are routinely used to speed wound drainage following surgery. One type of wound suction device includes a portable, relatively small suction chamber which is coupled to a source of body fluids. Applying reduced pressure to a wound may have several beneficial effects. One effect that it has is that the reduced pressure draws out exudate and necrotic tissue, which might contain dirt and bacteria, from the wound to further promote healing. Other benefits of applying reduced pressure to a wound include increasing perfusion to the wound and reduction of edema. Still other benefits of reduced pressure include retraction of the wound edges into the dressing, and removal of matrix metalloproteinase enzymes which inhibit granulation of tissue, and are related to tissue healing and remodeling, as well as to cancer metastasis. One other advantage of reduced pressure therapy is the fact that mechanical stimulation causes the natural release of growth factors by the cells in the wound body. All these benefits help to further promote wound healing.
Due to the benefits of reduced pressure therapy, it would be beneficial to develop reduced pressure therapy devices.
Generally described herein are tissue therapy devices. In one embodiment, the device comprises a sealant layer and a suction apparatus in fluid communication through the sealant layer. The sealant layer may be adapted and configured to create a sealed enclosure around an area of tissue requiring therapy. The suction apparatus may be adapted and configured to reduce pressure underneath the sealant layer. In addition, the suction apparatus may be adapted and configured to self-create the reduced pressure under the sealant layer. Moreover, the suction apparatus may be non-electrically powered. In some embodiments, the sealant layer and the suction apparatus form a closed reduced pressure system. In such embodiments, the closed system is resistant or not susceptible to the back streaming of gas. In some embodiments, the device is adapted and configured to create a generally airtight seal. In some embodiments, the device is adapted and configured to reduce pressure underneath the sealant layer by expanding the volume of air located in a joint volume of space shared between the sealed enclosure and the suction apparatus. In one embodiment of the device provided herein, the device delivers equivalent pressure levels and mechanical stimuli to the area to be treated. In some embodiments, the device may be adapted and configured to maintain the reduced pressure that the device creates.
In some embodiments, the level of reduced pressure may be applied and maintained for short periods of time or for extended periods of time. The reduced pressure may be applied and maintained for as short as approximately thirty (30) minutes or for as long as over 4 weeks or more. In some embodiments, the reduced pressure is applied for longer than 30 minutes. In some embodiments, the reduced pressure is applied for longer than 24 hours. In some embodiments, the reduced pressure is applied for longer than several days. In some embodiments, the reduced pressure is applied for longer than one week. In some embodiments, the reduced pressure is applied for longer than 4 weeks. In some embodiments, the device may incorporate an additional external suction apparatus if so desired.
In some embodiments, the reduced pressure is maintained by a ratcheting mechanism integrated with the suction apparatus. In some embodiments of the device, the suction apparatus also serves as a collection chamber. In some embodiments, the device further comprises an external collection chamber. In some embodiments, the tissue therapy device described herein further comprises a second suction apparatus.
In some embodiments, the device comprises a suction apparatus and a sealant layer in which the suction apparatus and sealant layer are separate structures. In some embodiments, the suction apparatus and the sealant layer are integrated into a single structure. In some embodiments of the device described herein, the suction apparatus may be disconnected from the sealant layer, emptied, and then reconnected to the sealant layer. In some embodiments of the device provided herein, the suction apparatus is disconnected and discarded. In such an embodiment, the suction apparatus may be replaced with a new second suction apparatus. In a further embodiment of the device, where the suction apparatus is replaced with a second suction apparatus, the second suction apparatus may be replaced with a suction apparatus that is of the same type as the first suction apparatus. In some embodiments, the second suction apparatus is different than the first suction apparatus. In some embodiments where the suction apparatus may be detached, the suction apparatus may be configured to be detached and reattached without disturbing the sealant layer or the airtight seal between the sealant layer and the skin of the patient.
In some of the embodiments, the tissue therapy device further comprises a one-way flow valve. In such an embodiment, the one-way flow valve may be adapted and configured to prevent exudate from returning to the section of tissue for which therapy is required and to which the reduced pressure is applied.
In some embodiments of the device, the device is configured to be portable. In a further embodiment of the device, the device is configured to be secured to the patient. Yet in other embodiments the device is configured to be wearable.
In some further embodiments, a tissue therapy device is provided, comprising a sealant layer, a suction apparatus, and a contact layer. In some embodiments of the device, the contact layer comprises a stacked mesh matrix. In some embodiments of the device, the contact layer and the sealant layer are separate structures. In some embodiments of the device, the contact layer and the sealant layer are integrated into a single structure. In another embodiment of the device, at least any two of the suction apparatus, the contact layer, or the sealant layer are integrated together while the third remains a separate structure. In some embodiments, the contact layer and the sealant layer are integrated together and the suction apparatus is a separate structure. In some embodiments, the contact layer and the suction apparatus are integrated together and the sealant layer is a separate structure. In some embodiments, the sealant layer and the suction apparatus are integrated together and the contact layer is a separate structure.
In some embodiments, the device further comprises a protective layer. The protective layer is placed around the area of tissue to be treated. In some embodiments the protective layer can be any suitable biocompatible polymer. In some embodiments of the device, the sealant layer may be any suitable biocompatible polymer.
In another embodiment, a mesh matrix is provided, comprising at least one mesh matrix sheet. In some embodiments, at least two mesh matrix sheets may be provided, wherein the mesh matrix sheets are adapted and configured to provide fluid communication between a suction apparatus and an area of damaged tissue. In some embodiments, the mesh matrix comprises two or more mesh matrix sheets. In some embodiments, multiple mesh matrix sheets may be arranged in stacked or layered configuration. The mesh matrix sheets may be separated to a desired thickness. In some embodiments, the mesh matrix sheet may be cut such that it conforms to an area or shape of tissue damage. In a further embodiment, the mesh matrix sheet comprises filaments. In some embodiments, the filaments are made of a polymer. In some embodiments, the filaments are aligned perpendicular or another angle to each other throughout the stacked mesh matrix. In other embodiments, the filaments are randomly oriented with respect to each other. In some embodiments, the filaments of the stacked mesh matrix are hollow. In some embodiments, the stacked mesh matrix further comprises a delivery mesh as one of the layers of the stacked mesh matrix. In some embodiments, the filaments of the delivery mesh are hollow.
In some embodiments, the contact layer of the tissue therapy device comprises an adjustable pouch containing one or more non-filamentous structures. The non-filamentous structures and the pouch may be adapted and configured to provide fluid communication between the suction apparatus and the area of tissue requiring treatment. In some embodiments the non filaments structures are made from a biocompatible polymer material. In some embodiments the pouch contains at least two structures. In some embodiments the pouch volume can be adjusted by adding or subtracting non-filamentous structures from the pouch without disturbing the integrity of the pouch.
In one embodiment, a tissue therapy device is provided, comprising a sealant layer, said sealant layer adapted and configured to create a sealed enclosure around an area of tissue requiring therapy, and a suction apparatus, said suction apparatus in fluid communication through the sealant layer with said enclosure and adapted and configured to self-create a reduced pressure level within said enclosure, wherein said sealant layer and said suction apparatus are adapted and configured to create a closed reduced pressure system, wherein the suction apparatus is configured to be portable. The sealant layer may be adapted and configured to create an airtight seal. The suction apparatus may be adapted and configured to expand a volume of air located in a joint volume of space shared between said sealed enclosure and said suction apparatus, and/or may be adapted and configured to decrease a density of air molecules under the sealant layer when said suction apparatus is engaged. In some embodiments, the suction apparatus may self-create a level of reduced pressure underneath said sealant layer, wherein said level of reduced pressure is between about 0 and about 760 mm Hg. The sealant layer shape may follow a perimeter of the area of tissue undergoing therapy. The device may be further adapted and configured to maintain a level of reduced pressure of between about 0 and about 760 mm Hg. The device may also be further adapted and configured to maintain a level of reduced pressure for an extended period of time. The suction apparatus may further comprise a retaining mechanism, and in some embodiments, the retaining mechanism is a ratcheting mechanism. The suction apparatus may further comprise a collection chamber, which may be an internal or an external collection chamber. The device may also further comprise a second suction apparatus. The suction apparatus and the sealant layer may be two separate structures, or may be integrated into a single structure. The suction apparatus may be adapted and configured to be disconnected from the sealant layer, emptied, and reconnected to the sealant layer, and in some embodiments, may be performed without disturbing the sealant layer. In some embodiments, the device may further comprise a second suction apparatus, wherein the second suction apparatus is adapted and configured to be connected to the sealant layer. The second suction apparatus may have a similar or a different configuration as the first suction apparatus. The suction apparatus may also further comprises a safety valve and/or a one-way flow valve, wherein said one-way flow valve is adapted and configured to prevent fluid from returning to the section of tissue requiring therapy. The suction apparatus is adapted and configured to be secured to a patient. The device may further comprise a securing member configured to attach the suction apparatus to a patient. The device may also further comprise a contact layer, which is may be a stacked mesh matrix. The contact layer and the sealant layer may be at least two separate structures or may be integrated into a single structure. In some embodiments, at least any two of the suction apparatus, the contact layer, or the sealant layer are integrated together while the third is a separate structure. For example, the contact layer and the sealant layer may be integrated together and the suction apparatus is a separate structure, or the contact layer and the suction apparatus are integrated together and the sealant layer is a separate structure. In another example, the sealant layer and the suction apparatus are integrated together and the contact layer is a separate structure. The device may also further comprise a protective layer placed around the area of tissue to be treated. In some embodiments, the sealant layer and/or the protective layer may be any biocompatible polymer.
In another embodiment, a tissue therapy device is provided, comprising a sealant layer, said sealant layer adapted and configured to create a sealed enclosure around an area of tissue, and a non electrically powered suction apparatus, said suction apparatus in fluid communication through the sealant layer with said enclosure and adapted and configured to self-create a reduced pressure level underneath the sealant layer, wherein said sealant layer and said suction apparatus are adapted and configured to create a closed reduced pressure system, wherein the suction apparatus is configured to be wearable.
In some embodiments, a stacked mesh matrix is provided, comprising at least two mesh matrix sheets, wherein said mesh matrix sheets are adapted and configured to provide fluid communication between a suction apparatus and an area of damaged tissue. The stacked mesh matrix may comprise multiple mesh matrix sheets. In some embodiments, mesh matrix sheets are further adapted and configured to be separated from each other. In some embodiments, at least one mesh matrix sheet is further adapted and configured to be cut to conform to the area of tissue damage. The mesh matrix sheets may comprise polymer filaments. The polymer filaments may be generally aligned perpendicular to each other, or may be non-uniformly oriented. The polymer filaments may have an average thickness of about 10 mm or less, or sometimes between about 0.001 mm and to about 10 mm in thickness. The polymer filaments may have of a uniform thickness, non-uniform thickness, or a random thickness throughout the stacked mesh matrix. In one embodiment, the polymer filaments of said mesh matrix sheet are about 1 mm to about 15 mm apart in spacing. The polymer filaments may be spaced a non-uniform or a uniform distance apart throughout the stacked mesh matrix. The polymer filaments may be hollow. The stacked mesh matrix may further comprise a delivery mesh matrix as one layer of the mesh matrix. The delivery mesh matrix may also comprise hollow polymer filaments.
In some embodiments, a contact layer is provided, comprising at least one non-planar structure adapted to provide fluid communication between the suction apparatus and the area of tissue requiring treatment. The non-planar structures are packed into adjustable porous pouch adapted to facilitate placement and replacement of said structure into the tissue cavity.
A better understanding of various features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Current negative pressure wound therapy (NPWT) systems use large, electrically driven mechanical pumps to deliver negative pressure to the treatment site. These pumps, however, limit a patient's mobility, requiring that the patient be connected to the system as well as a bulky power source throughout the course of treatment. NPWT is also very expensive, with the pump accounting for the majority of the costs.
Described generally herein are devices adapted and configured to provide reduced pressure to an area of tissue. Application of reduced pressure to an area of tissue may be used to create a therapeutic effect. In one embodiment what is described herein is a tissue therapy device. The device may be used to treat areas of tissue to which damage has occurred. In other embodiments the device may be used on non-damaged tissue.
In one embodiment, the tissue therapy device comprises a sealant layer and a suction apparatus. The sealant layer creates a seal around an area of tissue requiring therapy. The suction apparatus reduces pressure underneath the sealant layer. The reduction in pressure is self-created by the suction apparatus. In some embodiments the suction apparatus is non-electrically powered. In some embodiments, the sealant layer and the suction apparatus form a closed reduced pressure system. In such an embodiment, the closed system is not susceptible or resistant to the back streaming of gas. When the sealant layer is placed in contact with the patient, an airtight seal may be formed between the area surrounding the area of tissue to be treated and the sealant layer thereby creating a sealed enclosure. The suction apparatus then self-creates reduced pressure by expanding the volume of air located in a joint volume of space shared between the sealed enclosure and the suction apparatus by decreasing the density of the air molecules located in the volume of space created by the sealed enclosure. The suction apparatus may also serve as a collection chamber for collecting exudate drawn up out of the wound, for example.
In some embodiments, the suction apparatus is configured to self-create reduced pressure. When first positioned on the patient, the pressure underneath the sealed enclosure is typically at a pressure equal to the ambient atmospheric pressure. When the device is engaged, the level of pressure may be reduced. The level of pressure may be reduced to a therapeutic level. The device may self-create a reduced pressure underneath the sealant layer where the reduced pressure is anywhere between about 0 and about 760 millimeters of Mercury (mm Hg). In some embodiments, the device is adapted and configured to self-create a level of reduced pressure between approximately 0 and approximately 760 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 10 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 20 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 50 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 80 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 100 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 150 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 200 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 500 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is more than approximately 700 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 750 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 700 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 600 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 400 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 250 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 125 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 75 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 50 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 25 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is less than approximately 10 mm Hg. In some embodiments of the device described herein, the sealant layer generally follows the perimeter of the area of tissue requiring therapy.
In some embodiments, the device is positioned on the patient and reduced pressure is applied to the area of tissue to be treated. In a further embodiment, the device may augment the level of reduced pressure already present underneath the sealant layer of the device by further expanding the volume of air underneath the sealant layer. The volume of air may be expanded either by adjusting the suction apparatus used to initially create the reduced pressure or by attaching a second suction apparatus to further expand the volume of air underneath the sealant layer.
The tissue therapy device can have alternative embodiments of the suction apparatus for creating reduced pressure within the wound dressing. In one embodiment, the suction apparatus is non-electrically powered. In some embodiments, the suction apparatus is manually operated in order to create suction. In one embodiment, the suction apparatus comprises a closed collection chamber with fixed walls in which a reciprocating piece alters the volume of the collection chamber. In one embodiment, the suction apparatus is a syringe. In a further embodiment, the plunger of the syringe serves as the reciprocating mechanism of the suction apparatus. The suction apparatus is engaged by drawing back the reciprocating mechanism in order to create a reduction in pressure. In another alternate embodiment, a handle attached to the reciprocating mechanism of the syringe is employed to draw back the reciprocating mechanism. The reciprocating mechanism may be drawn back by any suitable means known to one skilled in the art. The drawing back of the reciprocating mechanism in the suction apparatus expands or enlarges the volume of the collection chamber inside of the suction apparatus. The collection chamber of the suction apparatus is in fluid communication with the sealed enclosure under the sealant layer of the wound dressing. The sealed enclosure under the wound dressing and the collection chamber of the suction device chamber are de-facto one chamber with a fixed amount of air molecules. Once the reciprocating mechanism is drawn back by increasing the volume of the collection chamber, the volume of the space occupied by the fixed amount of air molecules increases and density of the fixed amount of air molecules decreases. In another embodiment, the suction apparatus may be mechanically powered. In such an embodiment, the suction apparatus may be a mechanically powered vacuum pump.
In some embodiments, a sealant layer is provided. The sealant layer may be used to form a seal with the skin of the patient. In some embodiments, the seal is substantially airtight. Such a seal may be created around the perimeter of the area to be treated. In some embodiments, the seal is prefabricated into a fixed shape. In some embodiments, the fixed shape may be a circle, an oval, a square, a rectangle, a triangle, for example. In such an embodiment, the sealant layer may be shaped by the user to conform to the contours of the area to be treated.
In addition to self-creating reduced pressure, the suction apparatus of the tissue therapy device may also be adapted and configured to maintain a level of reduced pressure or a range of reduced pressures to be applied to the area of tissue to be treated. The level of reduced pressure may be maintained at a level anywhere between about 0 to about 760 mm Hg. In some embodiments, the device is configured to self-create reduced pressure without the use of electrical power. In a further embodiment, the device maintains the level of reduced pressure it self-creates, or a range of reduced pressures it self-creates. In some embodiments, the device maintains a level of reduced pressure between approximately 0 and approximately 760 mm Hg. In some embodiments the self-created level of reduced pressure in the sealed enclosure formed by the sealant layer is maintained at more than approximately 10 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 20 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 50 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 80 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 100 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 150 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 200 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 500 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at more than approximately 700 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 750 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 700 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 600 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 400 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 250 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 125 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 75 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 50 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 25 mm Hg. In some embodiments, the self-created level of reduced pressure in the enclosure formed by the sealant layer is maintained at less than approximately 10 mm Hg.
The level of reduced pressure may be applied and maintained by the reduced pressure tissue therapy device for short periods of time or for extended periods of time. In some embodiments, the reduced pressure may be applied and maintained for as short as approximately 30 minutes or for as long as over 4 weeks. In some embodiments, the reduced pressure is applied for longer than 30 minutes. In some embodiments the reduced pressure is applied for longer than 24 hours. In some embodiments, the reduced pressure is applied for longer than several days. In some embodiments, the reduced pressure is applied for longer than one week. In some embodiments, the reduced pressure is applied for longer than 4 weeks. In some embodiments, the device may incorporate an external suction apparatus if so desired.
The device can maintain the level of reduced pressure in several ways. In one embodiment, the device is engaged to create reduced pressure by engaging the non-electrical reciprocating mechanism located in the suction apparatus. In one embodiment, the resistance between the outside surfaces of the reciprocating mechanism and the inside surfaces of the suction apparatus are sufficient to maintain the level of reduced pressure underneath the sealant layer. In another embodiment, the suction apparatus is such that it further comprises a ratcheting mechanism. In one embodiment, the suction apparatus with ratcheting mechanism comprises a set of interlocking teeth integrated with the body of the suction apparatus and on sides of the reciprocating mechanism. The interlocking teeth resist or prevent the suction apparatus from losing its suction force by maintaining the position of the reciprocating mechanism in an extended position. This prevents or resists the shaft of the reciprocating mechanism from changing its position in response to the pressure inside the collection chamber. In another embodiment, the ratcheting system comprises a twist and lock mechanism which prevents the reciprocating mechanism from changing position in the suction apparatus.
In a further embodiment, the suction apparatus of the tissue therapy device may also serve as a collection chamber. The collection chamber includes a closed chamber, which may or may not be cylindrical in shape, in which a sliding or reciprocating piece or reciprocating mechanism may be manipulated to alter the volume of the collection chamber, thereby changing the density of the molecules located in the enclosure created by the sealant layer which is in fluid communication with the suction apparatus. In some embodiments, the suction apparatus may serve a two-fold function. The suction apparatus may be used to create the reduced pressure underneath the sealant layer of the wound dressing. The suction apparatus may also be used to collect exudate or necrotic debris that is drawn up out of the wound.
In some embodiments, the suction apparatus and the wound dressing may be separate pieces. In an alternate embodiment, the suction apparatus and the wound dressing may be attached together. In such an embodiment, the suction device is connected to the tissue therapy device and together both pieces are considered to be a single device. In some embodiments the wound dressing has a compression gasket attached to it, which provides for at least one attachment point for a suction apparatus to the wound dressing. In some embodiments, the compression gasket is such that there is more than one attachment point. In some embodiments, a single suction apparatus is attached to the attachment point of the compression gasket of the wound dressing to create negative pressure. In an alternative embodiment, a second suction apparatus may be attached to the compression gasket at a second attachment point located on the compression gasket. This embodiment may be used in order to collect a larger volume of exudate. In some embodiments, the volume of the suction apparatus chamber is between about 1ml and about 1000 ml. In some embodiments, the volume of the suction apparatus chamber may be about 1 ml. In some embodiments, the volume of the suction apparatus may be about 5 ml. In some embodiment, the suction apparatus may be about 10 ml. In some embodiments, the suction apparatus may be about 20 ml. In some embodiments, the suction apparatus may be about 30 ml. In some embodiments, the suction apparatus may be about 50 ml. In some embodiments, the suction apparatus may be about 100 ml. In some embodiments, the suction apparatus may be about 500 ml. In some embodiments the suction apparatus may be about 1000 ml or more.
In some embodiments, the suction apparatus may be disconnected from the wound dressing. For example, the suction apparatus may be disconnected from the wound dressing in order to empty the suction apparatus. In some specific examples, emptying the suction apparatus is performed when the amount of exudate in the suction apparatus reduces the effectiveness of the suction on the wound. In one embodiment, once the suction apparatus has been emptied, it can then be reconnected to the wound dressing. In an alternate embodiment, the suction apparatus is disconnected from the wound dressing and discarded and a new suction apparatus is attached to the wound dressing. In some embodiments, the suction apparatus replacing the discarded suction apparatus is the same kind of suction apparatus as the discarded suction apparatus. In other embodiments, the suction apparatus replacing the discarded suction apparatus is a different size or kind of suction apparatus than the discarded suction apparatus. For example, in some embodiments, the replacement suction apparatus may be smaller than the discarded suction apparatus. A smaller replacement suction apparatus may be used as the fluid and/or exudate secreted from a wound decreases over time, for example. In other examples, a larger suction apparatus may be provided during non-ambulatory periods (e.g. bedtime), while a smaller suction apparatus is provided during ambulatory periods. In some embodiments, the suction apparatus may be detached from the wound dressing while the reduced pressure created by the suction apparatus is maintained on the wound, even after the suction apparatus has been detached.
In some of the embodiments, the tissue therapy device is designed such that the device resists or prevents the backflow of exudate from the collection chamber of the suction device to the area of tissue to which therapy is applied. In some embodiments, the back flow is resisted or prevented by the inherent resistance of the suction apparatus. The inherent resistance may include but is not limited to the frictional resistance of the plunger, for example. In some embodiments, the tissue therapy device may include a one-way flow mechanism to prevent exudate from returning to the area of tissue requiring therapy or to the wound surface. In some embodiments, the one way flow mechanism may be a valve. In some embodiments, a filter or an absorbent structure, for example, may be provided to reduce redistribution of exudates, back to the treatment area.
In some embodiments, the tissue therapy device may be configured as a portable device that may be worn or carried by the patient or the patient's ambulation assistance device (e.g. wheelchair or walker). In other embodiments, the tissue therapy device is designed such that it may be secured to the patient (e.g. limb or torso). In some embodiments, the sealant layer is preferably adhered directly to the skin of the patient. The suction apparatus can then be put in fluid communication with the enclosure formed by the sealant layer. The sealant layer and the suction apparatus may be secured to the patient and carried around. In some of the embodiments mentioned, the tissue therapy device may be attached to the patient by any suitable means for securing the device to the patient. In some embodiments, the device is secured through the use of adhesive tape. In other embodiments, the device may be secured to the patient through the use of a strap, a hook-and-loop or a touch fastener such as VELCRO , an elastic band, a cuff, an adhesive bandage, or any other suitable mechanisms for securing the device to the patient. In some embodiments, the securing mechanism may be configured with a holster or other type of pocket structure to hold the suction apparatus. In some embodiments, the greater surface area of a cuff may reduce the risk of causing focal pressure points or regions as a result of securing the tissue therapy device. In some embodiments, a cuff having a longitudinal length of at least about half of its diameter is provided. In other embodiments, the cuff has a longitudinal length of at least about equal to its diameter. In other embodiments, the cuff may have a longitudinal length of at least about 1.2 times its diameter, sometimes at least about 1.5 times its diameter, and other times at least about 2 times or 3 times its diameter. In some embodiments, the securing device may comprise a band or cuff that is also be configured to apply an amount of pressure to the tissue surrounding the treatment area. This may be beneficial, for example, when the treatment area is a wound caused by venous stasis. The amount of pressure exerted by the securing device may be about 40 mm Hg or less, sometimes about 20 mm Hg or less and other times about 10 mm Hg or less, or about 6 mm Hg or less.
In one embodiment, the suction apparatus may be attached directly to the sealant layer by an attachment fitting. In another embodiment, fluid communication between the suction apparatus and the enclosure formed by the sealant layer may be provided by an extension tube. In this embodiment, the extension tube may be used to facilitate the attachment of the suction apparatus to the patient by permitting distance between the suction apparatus and the wound dressing and thereby allowing for placement of the suction apparatus where convenient.
In some embodiments of the wound therapy device described herein, a safety valve is included in the tissue therapy device. The safety valve may be a pressure-activated bleed valve that opens when excessively high negative pressure builds up in the device. In some embodiments, the safety valve opens in response to a set level of pressure.
In one embodiment of the tissue therapy device, the tissue therapy device may be used to provide therapy to a wound on the surface of the patient. In such an embodiment, in addition to the suction apparatus and the sealant layer, the tissue therapy device may comprise a contact layer. In some embodiments where a contact layer is used, the contact layer is placed in contact with a wound and not in contact with any surrounding tissue. In some embodiments, the contact layer is placed in contact with the wound and is in contact with the surrounding tissue. The sealant layer is then placed over the contact layer. The sealant layer creates a seal around the perimeter of the wound. In some embodiments the seal is airtight. The sealant layer then creates a seal with the surface of the skin by adhering to the surface surrounding the wound. In some embodiments, the sealant layer is integrated with the contact layer.
In some embodiments, the contact layer and the sealant layer may be integrated into the same structure. The contact layer may be configured to provide fluid communication between the suction apparatus and the wound surface. In some embodiments, any two of the sealant layer, the suction apparatus, or the contact layer may be integrated into the same structure while the third structure remains an independent separate structure. In some embodiments, the contact layer and the sealant layer are integrated together while the suction apparatus is a separate structure. In some embodiments, the contact layer and the suction apparatus are integrated together, while the sealant layer is a separate structure. In some embodiments, the sealant layer and the suction apparatus are integrated together while the contact layer is a separate structure.
In an embodiment comprising a contact layer, the contact layer may be any suitable material known in the art to serve as a protective layer to the wound itself. Examples of materials that may be used include, but are not limited to, gauze, foam, cotton, particulate material, and any other suitable protective material that is known in the art. In some embodiments a layer of a nonreactive or biocompatible material is placed on the wound surface prior to the contact layer being placed on the wound surface. The material may made from any suitable fluoropolymer, such as polytetrafluoroethylene (PTFE), perfluoroalkoxy polymer resin (PFA), fluorinated ethylene-propylene (FEP), polyethylenetetrafluoroethylene (ETFE), polyvinylfluoride (PVF), polyethylenechlorotrifluoroethylene (ECTFE), polyvinylidene fluoride (PVDF), polychlorotrifluoroethylene (PCTFE), or any other suitable nonreactive or biocompatible material or fluoropolymer known in the art. In some embodiments, the nonreactive or biocompatible material resists or prevents the wound from adhering to the contact layer.
In some embodiments, the contact layer of the tissue therapy device comprises a stacked mesh matrix. In some embodiments, the stacked mesh matrix comprises at least two mesh matrix sheets. In some embodiments, the stacked mesh matrix comprises multiple mesh matrix sheets. The stacked mesh matrix may be adapted and configured to provide fluid communication between the suction apparatus and an area of tissue which requires treatment.
In some embodiments, the contact layer of the tissue therapy device comprises an adjustable micro-particles pouch. The micro-particles and the pouch may be adapted and configured to provide fluid communication between the suction apparatus and the area of tissue requiring treatment. In some embodiments the micro-particles are made from a polymer material. In some embodiments the pouch contains at least two particles. In some embodiments the pouch volume can be adjusted by adding or subtracting micro-particles from the pouch without disturbing the integrity of the pouch.
In one embodiment, the contact layer may be prefabricated to a specific size and shape. In another embodiment, the contact layer may be prefabricated to a specific size and shape and then cut so that the prefabricated contact layer conforms to the shape or size of the wound.
In an embodiment where a stacked mesh matrix is used as the contact layer, the stacked mesh matrix comprises a series of thin filaments. In some embodiments, the filaments are made from a polymer material. The filaments of the stacked mesh matrix may be oriented such that the filaments lie perpendicular to one another. In some embodiments the filaments are randomly oriented. In some embodiments, the filaments are between approximately 0.001 mm to approximately 10 mm thick. In some embodiments, the filaments are more than approximately 0.01 mm thick. In some embodiments the filaments are more than approximately 0.05 mm thick. In some embodiments, the filaments are more than approximately 0.1 mm thick. In some embodiments the filaments are more than approximately 0.5 mm thick. In some embodiments, the filaments are more than approximately 1 mm thick. In some embodiments the filaments are more than approximately 2.5 mm thick. In some embodiments, the filaments are approximately more 5 mm thick. In some embodiments, the filaments are approximately more than 7.5 mm thick. In some embodiments, the filaments are approximately more than 10 mm thick. In some embodiments, the filaments are less than approximately 10 mm thick. In some embodiments, the filaments are less than approximately 5 mm thick. In some embodiments the filaments are less than approximately 1 mm thick. In some embodiments, the filaments are less than approximately 0.05 mm thick. In some embodiments the filaments are less than approximately 0.01 mm thick. In some embodiments the filaments are less than approximately 0.005 mm thick. In some embodiments, the filaments are less than 0.001 mm thick. In some embodiments, all the filaments throughout the stacked mesh matrix are of a uniform thickness. In other embodiments, the filament thickness is variable throughout the stacked mesh matrix.
In some embodiments of the wound therapy device, a mesh matrix sheet comprises filaments that are spaced between approximately 1 mm to 15 mm apart. In some embodiments the filaments are spaced more than about 1 mm apart. In some embodiments the filaments are spaced more than about 2 mm apart. In some embodiments the filaments are spaced about 4 mm apart. In some embodiments the filaments are spaced about 6 mm apart. In some embodiments the filaments are spaced about 8 mm apart. In some embodiments the filaments are space about 10 mm apart. In some embodiments the filaments are spaced about 12 mm apart. In some embodiments the filaments are spaced about 15 mm apart. In other embodiments the filaments are spaced between approximately 1 mm to approximately 5 mm apart. In some embodiments the filaments are spaced between approximately 5 mm to 10 mm apart. In some embodiments the filaments are spaced approximately 10 mm to 15 mm apart. In some embodiments, the filaments are spaced uniformly throughout the stacked mesh matrix. In other embodiments, the filaments are variably spaced throughout the stacked mesh matrix.
The stacked mesh matrix of the wound dressing may be designed to include other features. In some embodiments of the stacked mesh matrix, the stacked mesh matrix can deliver biologics to the wound through the filaments of a delivery mesh. In one embodiment of the stacked mesh matrix, the filaments of the delivery mesh are solid filaments soaked in a solution containing biologics or therapeutics. In an alternative embodiment of the stacked mesh matrix, the filaments of the delivery mesh are hollow. Examples of biologics to facilitate wound healing include, but are not limited to, antibiotics and growth factors. In other embodiments of the stacked mesh matrix, the delivery mesh may be used to irrigate the wound. In some embodiments where a delivery mesh is used, a separate external fluid source may be connected to the delivery mesh.
In another embodiment, the stacked mesh matrix comprises a single mesh matrix sheet. In another embodiment, the stacked mesh matrix comprises more than two or multiple mesh matrix sheets to create a multi-layered dressing. In this embodiment, the stacked mesh matrix may be separated to a desired thickness based on the thickness of the wound. In a further embodiment, the stacked mesh matrix may include a delivery mesh layer. In some embodiments, the delivery mesh is located on the bottom of the stacked mesh matrix. In some embodiments, the delivery mesh is located at the top of the stacked mesh matrix. In some embodiments, the delivery mesh is located anywhere but at the top or bottom of the stacked mesh matrix.
In some embodiments, a method for applying reduced pressure therapy to an area of tissue is provided, comprising creating a sealed enclosure around an area of tissue to be treated by affixing a sealant layer to a surface of a patient. Reduced pressure is then self-created underneath the sealant layer by expanding a volume of the air in the sealed enclosure using a suction apparatus in fluid communication with the sealed enclosure created by the sealant layer. In some embodiments the method uses a closed reduced pressure therapy system, comprising a sealant layer and a suction apparatus. In some embodiments, the sealed enclosure is air-tight. In some embodiments, the method further comprises providing a contact layer on the wound surface before the sealant layer is affixed to the surface of the patient. In some embodiments of the method described herein, the method further comprises applying a protective layer around the area of the tissue to be treated before creating the sealed enclosure. In some embodiments the method further comprises applying a hydrocolloid to the area of tissue to be treated. In some embodiments of the method described herein, the method further comprises creating reduced pressure with an external suction apparatus.
In some embodiments, a method of treating a wound using a reduced pressure therapy device is provided, comprising creating a sealed enclosure between a sealant layer of a wound dressing and the surface of a patient and applying self-created reduced pressure to a wound by forcefully expanding a volume of air molecules enclosed in the sealed enclosure. In some embodiments, the method uses a closed reduced pressure therapy system. In some embodiments, the wound to be treated is selected from an acute wound, a partial- or full-thickness burn, a surgically created wound or surgical dehiscence, neuropathic (diabetic) wounds, venous or arterial insufficiency ulcers, traumatic wounds, and pressure ulcers, and any other wound or damaged tissue for which the application of reduced pressure therapy is suitable.
In another embodiments, a method of treating an area of damaged tissue using reduced pressure tissue therapy is provided, comprising positioning a reduced pressure tissue therapy device over an area of tissue to be treated, where the reduced pressure tissue therapy device comprises a sealant layer and a suction apparatus, and reducing the level of pressure in a volume of air located under the sealant layer by engaging the suction apparatus, where the suction apparatus self-creates the reduction in pressure by forcefully expanding the volume of air under sealant layer and decreasing the density of the air molecules under the sealant layer. In some embodiments, the sealant layer and the suction apparatus form a closed reduced tissue therapy system.
Further depicted in
The suction apparatus 104 of the wound therapy device 100 may be connected to the wound dressing 102 by way of a compression fitting 122. The compression fitting 122 provides a mechanism or structure for attaching the suction apparatus 104 to the sealant layer 108. In some embodiments, the compression fitting 122 may comprise two or more components. For example,
The suction apparatus 104 may be attached to the attachment piece 124 of the compression fitting 122 using a compression gasket 128. In some embodiments, the compression gasket 128 may be inserted into the aperture 125 in the middle of the attachment pieces 124. The suction apparatus 104 is attached to the compression gasket 128 by inserting the neck of the suction apparatus 104 into a stem 132 of the compression gasket 128. In one embodiment the suction apparatus 104 may be attached to the compression gasket 128 by inserting the suction apparatus 104 into the compression gasket 128. Alternatively, in other embodiments, the suction apparatus 104 may be attached to the compression gasket 128 by screwing the suction apparatus 104 into the stem 132 of the compression gasket 128. In some of the previously described embodiments, the suction apparatus 104 may be easily detached and reattached if desired or required.
The tissue therapy device, as described herein, comprises a compression gasket 128 equipped with at least one stem 132 for attaching the suction apparatus. In some embodiments, the compression gasket may have a second connector 133 as shown in
In some embodiments, the suction opening in the tissue dressing may be pre-formed, but in some other embodiments, the suction opening may be formed at the point-of-use. In some embodiments, the dressing may comprise perforations, regions of reduced thickness, or other structural features that may be provided to facilitate formation of a suction opening. In some embodiments, more than one suction opening may be formed in the dressing, and more than one suction aperture forming structure may optionally provided.
In some embodiments, the wound therapy device incorporates a three-way valve 134. In one position, the valve allows exudate to be drawn up from the wound into the suction apparatus. In a second position the valve closes the communication between the wound dressing and the suction apparatus such that reduced pressure is maintained during emptying or replacement of the suction apparatus. In a third position, the valve allows fluid communication between the suction apparatus and an external collection chamber, while preventing exudate from returning to the wound surface.
Provided herein is a device for tissue therapy that delivers reduced pressure to an area of tissue. The tissue therapy device 200 is used by applying the wound dressing 202 of the device 200 to a patient 210 over a wound. The distal side of the sealant layer 208 together with the compression fitting 222 as placed on the patient is seen in
Also provided herein is a reduced pressure tissue therapy device 300 wherein the tissue therapy device is portable. The portability of the device allows the patient to remain mobile during use. In one embodiment, the wound dressing 302 is placed over the wound of the patient.
After the wound dressing has been positioned on a patient 310 as shown in
In yet another embodiment of the tissue therapy device, the suction apparatus 404 comprises a ratcheting mechanism. In such an embodiment, the reciprocating mechanism 438 of the suction apparatus 404 is engaged using a handle 458, as shown in
In other embodiments, other configurations for maintaining the position of the sliding seal or reciprocating mechanism may be used. For example, in some embodiments, a helical threaded interface may be provided between the actuator (e.g. plunger) and the suction chamber. To provide suction, the actuator may be rotated to move the sliding seal or reciprocating mechanism and to generate a reduced pressure. In some embodiments, the helical threaded interface may be located on an internal surface of the suction chamber and an outer surface of the actuator. In other embodiments, the threaded interface may be located on the outer surface of the suction chamber and an inner surface of an interface member coupled to the actuator or plunger. In still other embodiments, a clamp or an interference structure, such as a retaining pin, may be used to maintain the position of the sliding seal or reciprocating mechanism.
In some embodiments, the suction apparatus is attached directly to the wound dressing, as shown in
In an alternative embodiment, the suction apparatus 404 is attached to a wound dressing by a tube 472, as shown in
In one embodiment, the wound dressing and suction apparatus may be placed directly over the wound on the patient without any preparation of the patient and a seal is created between the sealant layer and the skin of the patient.
In some embodiments, a contact layer is positioned on the wound before the sealant layer is placed over the wound. In some embodiments, the contact is placed on the wound as a separate structure after being trimmed to accommodate the shape of the wound. In such an embodiment, the contact layer is in contact only with the wound surface and not in contact with any area surrounding the wound. In some embodiments, the contact layer is in contact with the tissue surrounding the wound. In some embodiments of the wound dressing, the contact layer is integrated into the sealant layer. In such an embodiment, the edges of the contact layer are not attached to the sealant layer and may be trimmed to accommodate the shape of the wound.
In one embodiment of the wound therapy device described herein, the wound dressing and vacuum chamber manifold is placed directly over the wound on the patient without any preparation of the patient and a seal is created between the sealant layer of the wound dressing and the skin of the patient. In this embodiment, when the wound dressing is removed from the skin of the patient when the wound dressing has to be changed, the seal is broken and a new seal is formed has to be formed between the skin and the new wound dressing.
In another embodiment of the device described herein, before the wound dressing is placed on the skin of a patient, a protective layer 574 is placed on the skin of the patient before the sealant layer of the wound dressing is put in contact with the skin of the patient, as shown in
In some embodiments, the protective layer may comprise an annular seal that may be placed around the wound area, rather than over the dressing. The dressing may be configured that could fit within the seal using a screw-in or a snap-in mechanism, for example. When the dressing is changed, the annular seal may remain fixed to the wound or treatment area while the dressing is replaced. In some embodiments, the dressing may be attached to the seal around a central region of the seal while the edges of the dressing are generally not attached to the seal. In some of these embodiments, the dressing may be trimmed to generally accommodate the shape of the wound.
Once the protective layer 674 has been placed around the wound 690, an integrated contact layer and sealant layer 602 connected to a suction apparatus 604 of a reduced pressure tissue therapy device 600 is placed over the first protective layer 674 as shown in
In some embodiments, the contact layer of the wound dressing comprises a stacked mesh matrix. The stacked mesh matrix 779 is shown in
The filaments 776 of the mesh matrix sheet 778 may be oriented such that they lie perpendicular in orientation to one another, or at some other angle. In other embodiments, the filaments may be oriented randomly within the sheet. In some embodiments of the wound therapy device, the stacked mesh matrix comprises mesh matrix sheets where the filaments of the mesh matrix sheet are spaced between approximately 1 mm to 15 mm apart. In some embodiments the filaments are spaced more than about 1 mm apart. In some embodiments the filaments are spaced more than about 2 mm apart. In some embodiments the filaments are spaced about 4 mm apart. In some embodiments the filaments are spaced about 6 mm apart. In some embodiments the filaments are spaced about 8 mm apart. In some embodiments the filaments are space about 10 mm apart. In some embodiments the filaments are spaced about 12 mm apart. In some embodiments the filaments are spaced about 15 mm apart. In other embodiments the filaments are spaced between approximately 1 mm to approximately 5 mm. In some embodiments the filaments are spaced between approximately 5 mm to 10 mm apart. In some embodiments the filaments 776 are spaced approximately 10 mm to 15 mm apart. In some embodiments, the filaments 776 are spaced uniformly throughout the mesh matrix sheet 778. In some embodiments, the filaments 776 are variably spaced throughout the mesh matrix sheet. In some aspects, the spacing between filaments is variable. In some aspects the filaments 776 may be hollow.
Each of the mesh structures may have a uniform or a non-uniform size, shape or configuration with respect to the other mesh structures. In some embodiments, one or more sheets may have a generally planar configuration, but in other embodiments, one or more sheets may have a non-planar configuration. In some embodiments, the edges of a mesh sheet may comprise the ends of the tubes that comprise the mesh sheet. In other embodiments, the mesh sheet may be configured with an annular edge comprising one or more tubes. In some embodiments, the annular edge may reduce the degree of tissue response to the mesh sheet compared to an edge comprising tube ends.
In some embodiments, the mesh sheet may be rigid, semi-rigid, or flexible. In some embodiments, the degree of flexibility may vary depending upon the degree of hydration of the mesh sheet. In embodiments, the degree of flexibility may be isotropic or anisotropic. In some embodiments, one or more mesh sheets may have a generally planar configuration, while in other embodiments, one or more mesh sheets may have a curved, corrugated, egg-crated shape, or other non-planar configuration. In some embodiments, the mesh matrix may comprise be arranged so that the configurations or orientations of adjacent mesh sheets are non-uniform. In embodiments where the mesh sheets are non-planar, small spaces may be formed between the adjacent mesh sheets. Depending upon the type of material comprising the mesh sheets, in some embodiments, the sheets may be adherent or non-adherent to each other with contact.
The filaments comprising a mesh sheet may be configured to have a length extending from one edge of a sheet to another edge of the sheet. In other embodiments, one or more filaments may have a length and orientation where the filaments ends are not located at an edge of the sheet. The filaments may have any of a variety of cross-sectional shapes, including but not limited to circles, ovals, squares, rectangles, triangles or any other polygonal or closed-ended shape. The cross-sectional shape or cross-sectional area of a filament need not be uniform along its longitudinal length. In some embodiments, a mesh sheet may further comprise a non-tubular or non-elongate structure, such as a disc or a cube. The non-tubular structures may comprise the same or a different material.
In some embodiments, one or mesh sheets may comprise one or more biodegradable or bioabsorbable materials. In some embodiments, the biodegradable materials may be metallic or non-metallic, including but not limited to biodegradable polymers. Examples of such polymers include but are not limited to various forms of polycaprolactone, poly (L-lactide)s, poly(DL-lactide)s, polyglycolide, poly(L-lactide-co-D, L-lLactide), Poly (DL-lactide-co-glycolide), poly(DL-lactide-co-caprolactone), polydioxanone, polyesteramide, copolyoxalate, poly (glutamic-co-leucine), and combinations thereof.
In addition to the spacing and size of the openings provided by the arrangement of the substructures that comprise a mesh sheet, the substructures themselves may also have a surface porosity. The pores may substantially uniform or non-uniform in size, shape and/or configuration. In some embodiments, the average surface porosity of a tube, for example, may be about 1 nm to about 500 μm or more, sometimes about 5 nm to about 100 μm, and other times about 50 nm to about 500 nm.
In addition to mesh sheets and layered mesh matrices, in other embodiments, the contact layer may comprise one or more non-sheet structures. In some embodiments, the contact layer may comprise a plurality of small, loose structures or particles that may have a generally two-dimensional or three-dimensional configuration. In some embodiments the non sheet structures may be packed into a porous pouch so as to enables easy placement and replacement of the non sheet structures from the damaged tissue cavity. These non-sheet structures may be used with or without mesh sheets. In some embodiments, the non-sheet structures may have any of a variety shapes, including but not limited to filaments, chips, ball, cube, conical, frusto-conical or pyramidal shapes, for example. Some of the shapes may have a complex, three-dimensional configuration. In
In some embodiments, the stacked mesh matrix 779 comprises at least two mesh matrix sheets 778. In some embodiments, the stacked mesh matrix 779 will comprises two mesh matrix sheets 778 of
In some embodiments, the reduced pressure tissue therapy device may include a delivery mesh to provide variable-pressure assisted irrigation or delivery of biologics to the wound. In some embodiments, the delivery mesh comprises filaments that are soaked with the solution to be delivered. In such an embodiment, the solution diffuses into the wound area from the filaments. In some embodiments, the reduced pressure tissue therapy device comprises a network of interconnected hollow tubes 813 arranged in a mesh-like configuration to form a delivery mesh 812, as seen in
Provided herein is a delivery mesh for the delivery of biologics or antibiotics to the wound. In such an embodiment, a solution containing biologics or antibiotics, or a solution suitable for delivery to a wound, may be delivered to the wound 990 from a fluid reservoir through a supply tube 914. The solution may be delivered to the wound through perforations 915 on the underside 916 of the delivery mesh 912 as seen in
In one embodiment of the reduced pressure tissue therapy device, the device and delivery mesh may be used in conjunction with a mechanical pump. In such an embodiment, the pump can deliver normal therapeutic reduced pressure, but may also be used to deliver positive therapeutic pressure to enhance distribution of solution to the wound. In such an embodiment, the delivery mesh 912 of
In another alternate embodiment, a sealed and evacuated bottle may be used as a vacuum source. In some embodiments, the bottle may comprise a screw-in connector. The receptacle for the bottle on the dressing may comprise a mechanism or structure to break a seal on the bottle when the bottle is connected, thereby applying the negative pressure from the bottle to the wound or tissue treatment site.
In some embodiments, the particles may be placed or packed into one or more porous pouches, which may be placed into a tissue cavity. The particles may be loosely packed, permitting substantial movement of particles within the pouch, or tightly packed, where significant particle movement is limited due to particle density. Typically, the porosity of the pouch is smaller than the average size of the particles, but in other embodiments, the porosity of the pouch may be greater. In some embodiments, one or more tubular structures may project out from the pores of the pouch but the particles do not separate from the pouch. In still other embodiments, the pouch is configured such that the particles or other components within the pouch may be released over time.
In some embodiments, the pouches are filled and sealed at the point-of-manufacture, while in other embodiments, the pouches are filled at the point-of-use.
In some embodiments, the pouch may be filled with a variable amount of particles or contact layer structures. In some embodiments, the structure of the pouch may be adjusted to different fill volumes. For example, the pouch 1018 depicted in
While various embodiments have been described and presented herein, those embodiments are provided by way of example only. Variations, changes and substitutions may be made without departing from the invention. It should be noted that various alternatives to the exemplary embodiments described herein may be employed in practicing the invention. For all of the embodiments described herein, the steps of the methods need not be performed sequentially.
This application claims benefit under 35 U.S.C. § 119(e) to a) U.S. Provisional Application Serial No. 60/973,086, filed on Sept. 17, 2007, and b) U.S. Provisional Application Serial No. 60/906,721, filed Mar. 14, 2007, which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 418469 | McKinley et al. | Dec 1889 | A |
| 617936 | Nicolas | Jan 1899 | A |
| 1355846 | Rannells | Oct 1920 | A |
| 2142624 | Williams | Jan 1939 | A |
| 2198666 | Gruskin | Apr 1940 | A |
| 2472116 | Maynes | Jun 1949 | A |
| 2523850 | Steinberg | Sep 1950 | A |
| 2547758 | Keeling | Apr 1951 | A |
| 2632443 | Lesher | Mar 1953 | A |
| 2660342 | Ruf | Nov 1953 | A |
| 2682873 | Evans et al. | Jul 1954 | A |
| 2863452 | Ogle, Sr. | Dec 1958 | A |
| 2910763 | Lauterbach | Nov 1959 | A |
| 2969057 | Simmons | Jan 1961 | A |
| 3066672 | Crosby, Jr. et al. | Dec 1962 | A |
| 3073309 | Mosier | Jan 1963 | A |
| 3334628 | Saemann et al. | Aug 1967 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3401522 | Hann et al. | Sep 1968 | A |
| 3520300 | Flower, Jr. | Jul 1970 | A |
| 3568675 | Harvey | Mar 1971 | A |
| 3583399 | Ritsky | Jun 1971 | A |
| 3628325 | Morita | Dec 1971 | A |
| 3648692 | Wheeler | Mar 1972 | A |
| 3680560 | Pannier, Jr. et al. | Aug 1972 | A |
| 3682180 | McFarlane | Aug 1972 | A |
| 3750393 | Minto et al. | Aug 1973 | A |
| 3779243 | Tussey et al. | Dec 1973 | A |
| 3809086 | Schachet et al. | May 1974 | A |
| 3809087 | Lewis, Jr. | May 1974 | A |
| 3826254 | Mellor | Jul 1974 | A |
| 3833030 | Waldbauer, Jr. et al. | Sep 1974 | A |
| 3841331 | Wilder et al. | Oct 1974 | A |
| 3864766 | Prete, Jr. | Feb 1975 | A |
| 3958570 | Vogelman et al. | May 1976 | A |
| 3982546 | Friend | Sep 1976 | A |
| 4041934 | Genese | Aug 1977 | A |
| 4067330 | Roache | Jan 1978 | A |
| 4080970 | Miller | Mar 1978 | A |
| 4096853 | Weigand | Jun 1978 | A |
| 4124116 | McCabe, Jr. | Nov 1978 | A |
| 4139004 | Gonzalez, Jr. | Feb 1979 | A |
| 4165748 | Johnson | Aug 1979 | A |
| 4184510 | Murry et al. | Jan 1980 | A |
| 4233969 | Lock et al. | Nov 1980 | A |
| 4245630 | Lloyd et al. | Jan 1981 | A |
| 4256109 | Nichols | Mar 1981 | A |
| 4261363 | Russo | Apr 1981 | A |
| 4275721 | Olson | Jun 1981 | A |
| 4278089 | Huck et al. | Jul 1981 | A |
| 4284079 | Adair | Aug 1981 | A |
| 4287819 | Emerit | Sep 1981 | A |
| 4297995 | Golub | Nov 1981 | A |
| 4333456 | Webb | Jun 1982 | A |
| 4333458 | Margulies et al. | Jun 1982 | A |
| 4333468 | Geist | Jun 1982 | A |
| 4373519 | Errede et al. | Feb 1983 | A |
| 4382441 | Svedman | May 1983 | A |
| 4392853 | Muto | Jul 1983 | A |
| 4392858 | George et al. | Jul 1983 | A |
| 4404924 | Goldberg et al. | Sep 1983 | A |
| 4419097 | Rowland | Dec 1983 | A |
| 4465485 | Kashmer et al. | Aug 1984 | A |
| 4475909 | Eisenberg | Oct 1984 | A |
| 4480638 | Schmid | Nov 1984 | A |
| 4484919 | Sohn et al. | Nov 1984 | A |
| 4525166 | Leclerc | Jun 1985 | A |
| 4525167 | Goldberg et al. | Jun 1985 | A |
| 4525374 | Vaillancourt | Jun 1985 | A |
| 4540412 | Van Overloop | Sep 1985 | A |
| 4543100 | Brodsky | Sep 1985 | A |
| 4548202 | Duncan | Oct 1985 | A |
| 4549554 | Markham | Oct 1985 | A |
| 4551139 | Plaas et al. | Nov 1985 | A |
| 4569348 | Hasslinger | Feb 1986 | A |
| 4569674 | Phillips et al. | Feb 1986 | A |
| 4578060 | Huck et al. | Mar 1986 | A |
| 4605399 | Weston et al. | Aug 1986 | A |
| 4608041 | Nielsen | Aug 1986 | A |
| 4640688 | Hauser | Feb 1987 | A |
| 4648870 | Goldberg et al. | Mar 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4664128 | Lee | May 1987 | A |
| 4664662 | Webster | May 1987 | A |
| 4710165 | McNeil et al. | Dec 1987 | A |
| 4733659 | Edenbaum et al. | Mar 1988 | A |
| 4743232 | Kruger | May 1988 | A |
| 4747960 | Freeman et al. | May 1988 | A |
| 4758220 | Sundblom et al. | Jul 1988 | A |
| 4758232 | Chak | Jul 1988 | A |
| 4787888 | Fox | Nov 1988 | A |
| 4810249 | Haber et al. | Mar 1989 | A |
| 4826494 | Richmond et al. | May 1989 | A |
| 4838883 | Matsuura | Jun 1989 | A |
| 4840187 | Brazier | Jun 1989 | A |
| 4863449 | Therriault et al. | Sep 1989 | A |
| 4867748 | Samuelson | Sep 1989 | A |
| 4872450 | Austad | Oct 1989 | A |
| 4878901 | Sachse | Nov 1989 | A |
| 4882337 | Sweet et al. | Nov 1989 | A |
| 4889250 | Beyer | Dec 1989 | A |
| 4897081 | Poirier et al. | Jan 1990 | A |
| 4906233 | Moriuchi et al. | Mar 1990 | A |
| 4906240 | Reed et al. | Mar 1990 | A |
| 4919654 | Kalt | Apr 1990 | A |
| 4941882 | Ward et al. | Jul 1990 | A |
| 4953565 | Tachibana et al. | Sep 1990 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 4985019 | Michelson | Jan 1991 | A |
| 5018516 | Gilman | May 1991 | A |
| 5037397 | Kalt et al. | Aug 1991 | A |
| 5067950 | Broadnax, Jr. | Nov 1991 | A |
| 5071409 | Rosenberg | Dec 1991 | A |
| 5073172 | Fell | Dec 1991 | A |
| 5086170 | Luheshi et al. | Feb 1992 | A |
| 5092858 | Benson et al. | Mar 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5107859 | Alcorn et al. | Apr 1992 | A |
| 5116310 | Seder et al. | May 1992 | A |
| 5134994 | Say | Aug 1992 | A |
| 5149331 | Ferdman et al. | Sep 1992 | A |
| 5154697 | Loori | Oct 1992 | A |
| 5157808 | Sterner, Jr. | Oct 1992 | A |
| 5167613 | Karami et al. | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5215522 | Page et al. | Jun 1993 | A |
| 5232453 | Plass et al. | Aug 1993 | A |
| 5261893 | Zamierowski | Nov 1993 | A |
| 5263922 | Sova et al. | Nov 1993 | A |
| 5266476 | Sussman et al. | Nov 1993 | A |
| 5278100 | Doan et al. | Jan 1994 | A |
| 5279550 | Habib et al. | Jan 1994 | A |
| 5284621 | Kaufman | Feb 1994 | A |
| 5298015 | Komatsuzaki et al. | Mar 1994 | A |
| 5342376 | Ruff | Aug 1994 | A |
| 5344415 | DeBusk et al. | Sep 1994 | A |
| 5356372 | Donovan et al. | Oct 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5380295 | Vacca | Jan 1995 | A |
| 5395345 | Gross | Mar 1995 | A |
| 5437622 | Carion | Aug 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5531999 | Cartmell et al. | Jul 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5556375 | Ewall | Sep 1996 | A |
| 5584801 | Kuroyanagi et al. | Dec 1996 | A |
| 5607388 | Ewall | Mar 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| H1687 | Roe et al. | Oct 1997 | H |
| 5701917 | Khouri | Dec 1997 | A |
| 5704905 | Jensen et al. | Jan 1998 | A |
| 5711969 | Patel et al. | Jan 1998 | A |
| 5845641 | Pinney et al. | Dec 1998 | A |
| 5961497 | Larkin | Oct 1999 | A |
| 5970979 | Christofel et al. | Oct 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6174306 | Fleischmann | Jan 2001 | B1 |
| 6211426 | Abrams | Apr 2001 | B1 |
| 6235964 | Kadash et al. | May 2001 | B1 |
| 6241747 | Ruff | Jun 2001 | B1 |
| 6258995 | Gilding et al. | Jul 2001 | B1 |
| 6261276 | Reitsma | Jul 2001 | B1 |
| 6266859 | Hernandez | Jul 2001 | B1 |
| 6287316 | Agarwal et al. | Sep 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6368305 | Dutton | Apr 2002 | B1 |
| 6387082 | Freeman | May 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6461467 | Blatchford et al. | Oct 2002 | B2 |
| 6467432 | Lewis et al. | Oct 2002 | B1 |
| 6488643 | Tumey et al. | Dec 2002 | B1 |
| 6493568 | Bell et al. | Dec 2002 | B1 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6695824 | Howard et al. | Feb 2004 | B2 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6755807 | Risk, Jr. et al. | Jun 2004 | B2 |
| 6800074 | Henley et al. | Oct 2004 | B2 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6825246 | Fatttman | Nov 2004 | B1 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6913573 | Viscomi et al. | Jul 2005 | B1 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 6986234 | Liedtke | Jan 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7117869 | Heaton et al. | Oct 2006 | B2 |
| 7198046 | Argenta et al. | Apr 2007 | B1 |
| 7216651 | Argenta et al. | May 2007 | B2 |
| 7273054 | Heaton et al. | Sep 2007 | B2 |
| 7316672 | Hunt et al. | Jan 2008 | B1 |
| 7341574 | Schreijag | Mar 2008 | B2 |
| 7448653 | Jensen et al. | Nov 2008 | B2 |
| 7461158 | Rider et al. | Dec 2008 | B2 |
| 7485112 | Karpowicz et al. | Feb 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| 7569745 | Sticklen et al. | Aug 2009 | B2 |
| 7597690 | Tanio et al. | Oct 2009 | B2 |
| D607112 | Rogers et al. | Dec 2009 | S |
| D618337 | Pratt et al. | Jun 2010 | S |
| 7763000 | Risk, Jr. et al. | Jul 2010 | B2 |
| 7771377 | Stapf et al. | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| D624177 | Pratt et al. | Sep 2010 | S |
| 7794438 | Henley et al. | Sep 2010 | B2 |
| 7837673 | Vogel | Nov 2010 | B2 |
| 7863495 | Aali | Jan 2011 | B2 |
| 7875761 | Budig et al. | Jan 2011 | B2 |
| 7880050 | Robinson et al. | Feb 2011 | B2 |
| 7926856 | Smutney et al. | Apr 2011 | B2 |
| 7928279 | Rosenberg | Apr 2011 | B2 |
| 7928281 | Augustine | Apr 2011 | B2 |
| 7942866 | Radl et al. | May 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 8007257 | Heaton et al. | Aug 2011 | B2 |
| 8007491 | Pinto et al. | Aug 2011 | B2 |
| 8128607 | Hu et al. | Mar 2012 | B2 |
| 8148595 | Robinson et al. | Apr 2012 | B2 |
| 8162908 | Hu et al. | Apr 2012 | B2 |
| 8177764 | Hu et al. | May 2012 | B2 |
| 8287507 | Heaton et al. | Oct 2012 | B2 |
| 8308705 | Lin et al. | Nov 2012 | B2 |
| 8337474 | Hu et al. | Dec 2012 | B2 |
| 8361043 | Hu et al. | Jan 2013 | B2 |
| 8409156 | Kazala, Jr. et al. | Apr 2013 | B2 |
| 8409157 | Haggstrom et al. | Apr 2013 | B2 |
| 8409160 | Locke et al. | Apr 2013 | B2 |
| 8535283 | Heaton et al. | Sep 2013 | B2 |
| 8641692 | Tout et al. | Feb 2014 | B2 |
| 8679079 | Heaton et al. | Mar 2014 | B2 |
| 8864748 | Coulthard et al. | Oct 2014 | B2 |
| 20010031943 | Urie | Oct 2001 | A1 |
| 20010043943 | Coffey | Nov 2001 | A1 |
| 20020077661 | Saadat | Jun 2002 | A1 |
| 20020115951 | Norstrem et al. | Aug 2002 | A1 |
| 20020120185 | Johnson | Aug 2002 | A1 |
| 20020143286 | Tumey | Oct 2002 | A1 |
| 20020150720 | Howard et al. | Oct 2002 | A1 |
| 20020173808 | Houser et al. | Nov 2002 | A1 |
| 20020183702 | Henley et al. | Dec 2002 | A1 |
| 20020198503 | Risk, Jr. et al. | Dec 2002 | A1 |
| 20030050594 | Zamierowski | Mar 2003 | A1 |
| 20030088201 | Darcey | May 2003 | A1 |
| 20030120194 | Stapf | Jun 2003 | A1 |
| 20030190339 | Skover et al. | Oct 2003 | A1 |
| 20040249353 | Risks, Jr. et al. | Dec 2004 | A1 |
| 20040261642 | Hess | Dec 2004 | A1 |
| 20050020980 | Inoue et al. | Jan 2005 | A1 |
| 20050101940 | Radl et al. | May 2005 | A1 |
| 20050192544 | Wolbring et al. | Sep 2005 | A1 |
| 20050222527 | Miller et al. | Oct 2005 | A1 |
| 20050261642 | Weston | Nov 2005 | A1 |
| 20050267433 | Tanio et al. | Dec 2005 | A1 |
| 20060253090 | Bradley et al. | Nov 2006 | A1 |
| 20060282028 | Howard et al. | Dec 2006 | A1 |
| 20070027414 | Hoffman et al. | Feb 2007 | A1 |
| 20070066946 | Haggstrom et al. | Mar 2007 | A1 |
| 20070066948 | Erdman | Mar 2007 | A1 |
| 20070219512 | Heaton et al. | Sep 2007 | A1 |
| 20070219532 | Karpowicz et al. | Sep 2007 | A1 |
| 20070233022 | Henley et al. | Oct 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20080004559 | Riesinger | Jan 2008 | A1 |
| 20080009812 | Riesinger | Jan 2008 | A1 |
| 20080033330 | Moore | Feb 2008 | A1 |
| 20080063615 | MacDonald et al. | Mar 2008 | A1 |
| 20080082059 | Fink et al. | Apr 2008 | A1 |
| 20080086214 | Hardin et al. | Apr 2008 | A1 |
| 20080108977 | Heaton et al. | May 2008 | A1 |
| 20080200906 | Sanders et al. | Aug 2008 | A1 |
| 20080234641 | Locke et al. | Sep 2008 | A1 |
| 20080294147 | Radl et al. | Nov 2008 | A1 |
| 20080306448 | Lee | Dec 2008 | A1 |
| 20080306456 | Riesinger | Dec 2008 | A1 |
| 20090076467 | Pinto et al. | Mar 2009 | A1 |
| 20090187130 | Asmus et al. | Jul 2009 | A1 |
| 20090221977 | Blott et al. | Sep 2009 | A1 |
| 20090240218 | Braga et al. | Sep 2009 | A1 |
| 20090254066 | Heaton et al. | Oct 2009 | A1 |
| 20100030166 | Tout et al. | Feb 2010 | A1 |
| 20100036333 | Schenk, III et al. | Feb 2010 | A1 |
| 20100042059 | Pratt et al. | Feb 2010 | A1 |
| 20100100063 | Joshi et al. | Apr 2010 | A1 |
| 20100137775 | Hu et al. | Jun 2010 | A1 |
| 20100145289 | Lina et al. | Jun 2010 | A1 |
| 20100160879 | Weston | Jun 2010 | A1 |
| 20100160901 | Hu et al. | Jun 2010 | A1 |
| 20100168719 | Chen | Jul 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100179493 | Heagle et al. | Jul 2010 | A1 |
| 20100198174 | Hu et al. | Aug 2010 | A1 |
| 20100228205 | Hu et al. | Sep 2010 | A1 |
| 20100262090 | Riesinger | Oct 2010 | A1 |
| 20100262094 | Walton et al. | Oct 2010 | A1 |
| 20100324510 | Andresen et al. | Dec 2010 | A1 |
| 20110106030 | Scholz | May 2011 | A1 |
| 20110130691 | Hu et al. | Jun 2011 | A1 |
| 20110137270 | Hu et al. | Jun 2011 | A1 |
| 20110313377 | Pinto et al. | Dec 2011 | A1 |
| 20120016325 | Pinto et al. | Jan 2012 | A1 |
| 20120078207 | Hu et al. | Mar 2012 | A1 |
| 20130006204 | Hu et al. | Jan 2013 | A1 |
| 20130090615 | Jaeb et al. | Apr 2013 | A1 |
| 20130096536 | Kazala, Jr. et al. | Apr 2013 | A1 |
| 20140100539 | Coulthard et al. | Apr 2014 | A1 |
| 20140200535 | Locke et al. | Jul 2014 | A1 |
| 20150018784 | Coulthard et al. | Jan 2015 | A1 |
| 20150094673 | Pratt et al. | Apr 2015 | A1 |
| 20150094674 | Pratt et al. | Apr 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 550575 | Mar 1986 | AU |
| 745271 | Mar 2002 | AU |
| 755496 | Dec 2002 | AU |
| 2005436 | Jun 1990 | CA |
| 1438904 | Aug 2003 | CN |
| 2851641 | Dec 2006 | CN |
| 26 40 413 | Mar 1978 | DE |
| 43 06 478 | Sep 1994 | DE |
| 29 504 378 | Sep 1995 | DE |
| 19517699 | Nov 1996 | DE |
| 202004017052 | Jul 2005 | DE |
| 20 2005 019 670 | Jun 2006 | DE |
| 0100148 | Feb 1984 | EP |
| 0117632 | Sep 1984 | EP |
| 0161865 | Nov 1985 | EP |
| 0358302 | Mar 1990 | EP |
| 0360329 | Mar 1990 | EP |
| 1018967 | Jul 2000 | EP |
| 1163907 | Oct 1958 | FR |
| 2574299 | Jun 1986 | FR |
| 692578 | Jun 1953 | GB |
| 2 195 255 | Apr 1988 | GB |
| 2 195 255 | Apr 1988 | GB |
| 2 197 789 | Jun 1988 | GB |
| 2 220 357 | Jan 1990 | GB |
| 2 235 877 | Mar 1991 | GB |
| 2 306 107 | Apr 1997 | GB |
| 2 329 127 | Mar 1999 | GB |
| 2 333 965 | Aug 1999 | GB |
| 2 431 351 | Apr 2007 | GB |
| 55-068370 | May 1980 | JP |
| 59-177055 | Oct 1984 | JP |
| 04-506760 | Nov 1992 | JP |
| 11-504833 | May 1999 | JP |
| 2003-284770 | Oct 2003 | JP |
| 2003-532504 | Nov 2003 | JP |
| 2007-534403 | Nov 2007 | JP |
| 4129536 | Aug 2008 | JP |
| 2010506615 | Mar 2010 | JP |
| 71559 | Apr 2002 | SG |
| 8002182 | Oct 1980 | WO |
| 1980002182 | Oct 1980 | WO |
| WO-8002182 | Oct 1980 | WO |
| 8704626 | Aug 1987 | WO |
| 90010424 | Sep 1990 | WO |
| WO-9100718 | Jan 1991 | WO |
| 93009727 | May 1993 | WO |
| 94020041 | Sep 1994 | WO |
| 9605873 | Feb 1996 | WO |
| WO-9635401 | Nov 1996 | WO |
| 9718007 | May 1997 | WO |
| 9913793 | Mar 1999 | WO |
| WO-0185248 | Nov 2001 | WO |
| 2005051461 | Jun 2005 | WO |
| 2005105179 | Nov 2005 | WO |
| WO-2006005939 | Jan 2006 | WO |
| 2006048240 | May 2006 | WO |
| WO-2007030601 | Mar 2007 | WO |
| WO-2007030601 | Mar 2007 | WO |
| WO-2007067685 | Jun 2007 | WO |
| WO-2007067685 | Jun 2007 | WO |
| 2007123451 | Nov 2007 | WO |
| 2008048527 | Apr 2008 | WO |
| WO-2008100446 | Aug 2008 | WO |
| WO-2008100446 | Aug 2008 | WO |
| WO-2008112304 | Sep 2008 | WO |
| WO-2009002260 | Dec 2008 | WO |
| WO-2009089016 | Jul 2009 | WO |
| WO-2009103031 | Aug 2009 | WO |
| WO-2010068502 | Jun 2010 | WO |
| WO-2010080907 | Jul 2010 | WO |
| WO-2010102146 | Sep 2010 | WO |
| 2013078214 | May 2013 | WO |
| Entry |
|---|
| US 7,186,244, 03/2007, Hunt et al. (withdrawn) |
| Definition of “atmosphere”, Merriam-Webster OnLine. |
| Computer Desktop Encyclopedia, 1981. |
| McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, 2003. |
| International Search Report dated Jul. 28, 2008, for PCT Application No. PCT/US08/03412, filed on Mar. 13, 2008, three pages. |
| Chariker, M.E. et al. (Jun. 1989). “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery 34:59-63. |
| Davydov, Y.A. et al. (Sep. 1986). “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis,” The Kremlin Papers: Perspectives in Wound Care pp. 5-7. (English Translation of Vestnik Khirurgii article.). |
| Davydov, Y.A. et al. (Oct. 1988). “The Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds,” The Kremlin Papers: Perspectives in Wound Care pp. 11-14. (English Translation of Vestnik Khirurgii article.). |
| Davydov, Y.A. et al. (Feb. 1991). “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy,” The Kremlin Papers: Perspectives in Wound Care pp. 15-17. (English Translation of Vestnik Khirurgii article.). |
| Kostiuchenok, B.M. et al. (Sep. 1986). “The Vacuum Effect in the Surgical Treatment of Purulent Wounds,” The Kremlin Papers: Perspectives in Wound Care pp. 3-4. (English Translation of Vestnik Khirurgii article.). |
| Meyer, D.C. et al. (Jun. 2005). “Weight-Loaded Syringes as a Simple and Cheap Alternative to Pumps for Vacuum-Enhanced Wound Healing,” Plastic and Reconstructive Surgery 115(7):2174-2176, located at <http://gateway.tx.ovid.com.laneproxy.stanford.edu/gw2/ovidweb.cgi>, last visited on Oct. 15, 2007. |
| Usupov, Y.N. et al. (Apr. 1987). “Active Wound Drainage,” The Kremlin Papers: Perspectives in Wound Care pp. 8-10. (English Translation of Vestnik Khirurgii article.). |
| Anonymous. (Feb. 10, 2000). “Drain and Suture Line Care for Wounds,” The Cleveland Clinic Foundation, located at <http://www.clevelandclinic.org/health/health-info/docs/2200/2205.asp?i . . . >, last visited Oct. 15, 2007, four pages. |
| Bagautdinov, N.A. (1986). “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in Current Problems in Modern Clinical Surgery, Volkov, V.Y. et al. eds., Cheboksary: Chuvashia State University, 14 pages. (includes English translation and translation certifications). |
| Herrmann, L.G. et al. (1934). “The Conservative Treatment of Arteriosclerotic Peripheral Vascular Diseases: Passive Vascular Exercises (Pavaex Therapy),” Ann. Surgery pp. 750-760. |
| International Preliminary Report on Patentability dated Sep. 24, 2009, for PCT Application No. PCT/US2008/003412, filed Mar. 13, 2008, 7 pages. |
| International Search Report dated May 29, 2009, for PCT Application No. PCT/US2009/034158, filed Feb. 13, 2009, 2 pages. |
| Non-Final Office Action dated Oct. 29, 2009, for U.S. Appl. No. 12/234,530, filed Sep. 19, 2008, 14 pages. |
| Svedman, P. (Sep. 3, 1983). “Irrigation Treatment of Leg Ulcers,” The Lancet pp. 532-534. |
| Svedman, P. et al. (Aug. 1986). “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery 17(2):125-133. |
| Ubbink, D.T. et al. (2009). “Topical Negative Pressure for Treating Chronic Wounds,” The Cochrane Collaboration 3:1-32. |
| Urschel, J.D. et al. (1988). “The Effect of Mechanical Stress on Soft and Hard Tissue Repair; a Review,” British Journal of Plastic Surgery 41:182-186. |
| U.S. Appl. No. 12/372,661, filed Feb. 17, 2009, by Hu et al. |
| International Search Report dated Jan. 21, 2010, for PCT Application No. PCT/US09/65959, filed on Nov. 25, 2009, 5 pages. |
| International Search Report dated May 4, 2010, for PCT Application No. PCT/US2010/026269, filed on Mar. 4, 2010, 4 pages. |
| Written Opinion of the International Searching Authority dated Jan. 21, 2010, for PCT Application No. PCT/US09/65959, filed on Nov. 25, 2009, 7 pages. |
| Written Opinion dated May 4, 2010, for PCT Application No. PCT/US2010/026269, filed on Mar. 4, 2010, 7 pages. |
| Final Office Action dated Apr. 22, 2010, for U.S. Appl. No. 12/234,530, filed Sep. 19, 2008, 16 pages. |
| Non-Final Office Action dated Oct. 12, 2011, for U.S. Appl. No. 12/626,426, filed Nov. 25, 2009, 14 pages. |
| Non-Final Office Action dated Oct. 31, 2011, for U.S. Appl. No. 13/030,042, filed Feb. 17, 2011, 17 pages. |
| Non-Final Office Action dated Nov. 2, 2011, for U.S. Appl. No. 12/646,856, filed Dec. 23, 2009, 15 pages. |
| Non-Final Office Action dated Nov. 18, 2011, for U.S. Appl. No. 13/245,735, filed Sep. 26, 2011, 13 pages. |
| Non-Final Office Action dated Dec. 23, 2011, for U.S. Appl. No. 13/245,746, filed Sep. 26, 2011, 10 pages. |
| Notice of Allowance dated Dec. 22, 2011, for U.S. Appl. No. 12/760,406, filed Apr. 14, 2010, eight pages. |
| Pre-Interview First Office Action dated Dec. 15, 2011, for U.S. Appl. No. 12/372,661, filed Feb. 17, 2009, three pages. |
| Final Office Action dated Jul. 26, 2012, for U.S. Appl. No. 12/646,856, filed Dec. 23, 2009, 18 pages. |
| Final Office Action dated Aug. 31, 2012, for U.S. Appl. No. 12/646,426, filed Dec. 23, 2009, 21 pages. |
| Final Office Action dated Aug. 31, 2012, for U.S. Appl. No. 13/030,042, filed Dec. 23, 2009, 21 pages. |
| Fletcher, J. (May 2007). “World Wide Wounds, Dressings: Cutting and Application Guide,” located at <http://www.worldwidewounds.com/2007/may/Fletcher-Dressings-Cutting-Guide.html>, 15 pages. |
| Girolami, S. “Bio-Dome™ Technology: The Newest Approach to Negative Pressure wound Therapy,” 1 page. |
| Gokoo, C.F. et al. (1997). “Evaluation of Sacral shaped Transparent Dressing Over Contoured and High Stress Areas,” 4 pages. |
| Gupta, S. (Jan. 2007). “Differentiating Negative Pressure Wound Therapy Devices: An Illustrative Case Series,” Wounds 19(1 Suppl):1-9. |
| International Preliminary Report on Patentability dated Aug. 17, 2010, for PCT Application No. PCT/US2009/034158, filed Feb. 13, 2009, eight pages. |
| International Preliminary Report on Patentability dated Jun. 9, 2011, for PCT Application No. PCT/US2009/065959, filed Nov. 25, 2009, ten pages. |
| International Preliminary Report on Patentability dated Jul. 12, 2011, for PCT Patent Application No. PCT/US2010/020368, filed on Jan. 7, 2010, 6 pages. |
| International Preliminary Report on Patentability dated Sep. 6, 2011, for PCT Application No. PCT/US2010026269, filed Mar. 4, 2010, eight pages. |
| International Search Report dated Feb. 26, 2010, for PCT Patent Application No. PCT/US2010/020368, filed on Jan. 7, 2010, 2 pages. |
| Merriam-Webster definition of “mask”, located at <http://www.merriam-webster.com/medical/mask>, last visited Aug. 25, 2012, 2 pages. |
| Non-Final Office Action dated Jun. 28, 2012, for U.S. Appl. No. 12/717,838, filed Mar. 4, 2010, 13 pages. |
| Non-Final Office Action dated Nov. 5, 2012, for U.S. Appl. No. 12/683,987, filed Jan. 7, 2010, 19 pages. |
| Notice of Allowance dated Jun. 24, 2011, for U.S. Appl. No. 12/234,530, filed Sep. 19, 2008, 11 pages. |
| Notice of Allowance dated Mar. 7, 2012, for U.S. Appl. No. 13/245,735, filed Sep. 26, 2011, seven pages. |
| Notice of Allowance dated Apr. 9, 2012, for U.S. Appl. No. 12/372,661, filed Feb. 17, 2009, five pages. |
| Notice of Allowance dated Jul. 17, 2012, for U.S. Appl. No. 12/760,409, filed Apr. 14, 2010, sixteen pages. |
| Notice of Allowance dated Dec. 10, 2012, for U.S. Appl. No. 12/683,987, filed Jan. 7, 2010, 7 pages. |
| Notice of Reasons for Rejection dated Jun. 19, 2012, for Japanese Patent Application No. 2010-546944, filed on Feb. 13, 2009, four pages. |
| PolyMem Quadrafoam, located at <http://www.verebrun.com.>, 4 pages. |
| PolyMem QuadraFoam, Case Study, Huge Saral Pressure Ulcer in Four Months Using PolMen Silver and PolyMem Wic Silver Dressings, Poster, presented at 17th Conference of the European Wound Management Association, Glasgow, Scotland, May 2-4 2007, 2 pages. |
| U.S. Appl. No. 13/615,173, filed Sep. 13, 2012, by Hu et al. |
| U.S. Appl. No. 13/752,206, filed Jan. 28, 2013, by Hu et al. |
| Wicks, G. (2007). “A Guide to the Treatment of Pressure Ulcers from Grade 1-Grade 4,” Wound Essentials 2:106,108,110,112-113. |
| Written Opinion dated Jul. 28, 2008, for PCT Application No. PCT/US08/03412, filed Mar. 13, 2008, five pages. |
| Written Opinion dated May 29, 2009, for PCT Application No. PCT/US2009/034158, filed Feb. 13, 2009, seven pages. |
| Written Opinion dated Feb. 26, 2010, for PCT Patent Application No. PCT/US2010/020368, filed on Jan. 7, 2010, 5 pages. |
| 3M TEGADERM Hydrocolloid Dressing, Sacral-6-3/4″ x 6-3/8″, 1 page. |
| Adhesive Sacral Dressing, Smith & Nephew, 3 pages. |
| EuroMed, Hydrocolloid Health Technologies, Product Catalog, 11 pages. |
| Non Final Office Action received for U.S. Appl. No. 13/030,042, dated May 8, 2013, 19 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/245,746, dated May 29, 2013, 10 pages. |
| Non Final Office Action received for U.S. Appl. No. 13/221,734, dated Jul. 19, 2013, 9 pages. |
| Advisory Action received for U.S. Appl. No. 12/717,838, dated Jul. 5, 2013, 2 pages. |
| Office Action received for Australian Patent Application No. 2009214439, dated May 9, 2013, 3 pages. |
| Office Action received for Chinese Patent Application No. 200980112984.X, dated Dec. 4, 2012, 13 pages (5 pages of English Translation and 8 pages of Official Copy). |
| Office Action received for Chinese Patent Application No. 200980112984.X, dated Aug. 16, 2013, 11 pages (4 pages of English Translation and 7 pages of Office Action). |
| Office Action received for Japanese Patent Application No. 2012-229673, dated Sep. 17, 2013, 5 pages (3 pages of English Translation and 2 pages of Office Action). |
| Extended European Search Report (includes Supplementary European Search Report and Search Opinion) received for European Patent Application No. 08726845.4, dated Jun. 20, 2014, 7 pages. |
| Decision to Grant received for European Patent Application No. 09709714.1, dated Sep. 11, 2014, 2 pages. |
| Intention to Grant received for European Patent Application No. 09709714.1, dated Apr. 29, 2014, 8 pages. |
| Decision to Grant received for European Patent Application No. 09832371.0, dated Oct. 16, 2014, 2 pages. |
| Intention to Grant received for European Patent Application No. 09832371.0, dated Jun. 2, 2014, 5 pages. |
| Office Action received for European Patent Application No. 09832371.0, dated Oct. 30, 2013, 5 pages. |
| Final Office Action received for U.S. Appl. No. 12/626,426, dated Jan. 3, 2014, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 12/626,426, dated Dec. 23, 2014, 14 pages. |
| Advisory Action received for U.S. Appl. No. 12/646,856, dated Jan. 29, 2014, 3 pages. |
| Final Office Action received for U.S. Appl. No. 12/646,856, dated Nov. 4, 2013, 19 pages. |
| Notice of Allowance received for U.S. Appl. No. 12/717,838, dated Jan. 8, 2014, 10 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/020,685, dated Feb. 14, 2014, 9 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/020,685, dated Oct. 15, 2014, 9 pages. |
| Final Office Action received for U.S. Appl. No. 13/030,042, dated Mar. 14, 2014, 26 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/030,042, dated Apr. 10, 2015, 27 pages. |
| Non Final Office Action received for U.S. Appl. No. 13/077,857, dated Apr. 24, 2015, 9 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 13/077,857, dated Jul. 17, 2014, 12 pages. |
| Final Office Action received for U.S. Appl. No. 13/221,734 dated Feb. 26, 2014, 13 pages. |
| Final Office Action received for U.S. Appl. No. 13/221,734, dated Apr. 9, 2015, 9 pages. |
| Non Final Office Action received for U.S. Appl. No. 13/221,734 dated Oct. 29, 2015, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/221,734, dated Jun. 19, 2014, 11 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/615,173, dated Sep. 24, 2014, 7 pages. |
| Final Office Action received for U.S. Appl. No. 13/752,206, dated Oct. 31, 2014, 12 pages. |
| Non Final Office Action received for U.S. Appl. No. 13/752,206, dated Apr. 23, 2015, 6 pages. |
| Non-Final Office Action received for U.S. Appl. No. 13/752,206, dated Apr. 29, 2014, 14 pages. |
| Notice of Allowance received for U.S. Appl. No. 13/752,206, dated Oct. 7, 2015, 7 pages. |
| Extended European Search Report received for European Patent Application No. 13152745.9, dated Oct. 9, 2015, 5 pages. |
| Extended European Search Report (includes Supplementary European Search Report and Search Opinion) received for European Patent Application No. 14187150.9, dated Dec. 10, 2014, 6 pages. |
| Office Action received for European Patent Application No. 14187150.9, dated Sep. 11, 2015, 4 pages. |
| Notice of Allowance received for Canadian Patent Application No. 2,715,645, dated Mar. 12, 2015, 1 page. |
| Notice of Acceptance received for Australian Patent Application No. 2009214439, dated Sep. 10, 2014, 2 pages. |
| Office Action received for Australian Patent Application No. 2009214439, dated Jul. 1, 2014, 4 pages. |
| Office Action received for Australian Patent Application No. 2009324913, dated Feb. 24, 2015, 4 pages. |
| Office Action received for Chinese Patent Application No. 200980112984.X, dated Mar. 19, 2014, 4 pages (2 pages of English Translation and 2 pages of Official Copy). |
| Notice of Allowance received for Japanese Patent Application No. 2010-546944, dated Mar. 3, 2014, 3 pages (Official Copy only). |
| Office Action received for Japanese Patent Application No. 2010-546944, dated Apr. 1, 2013, 5 pages (3 pages of English Translation and 2 pages of Official Copy). |
| Notice of Allowance received for Japanese Patent Application No. 2011-537745, dated Dec. 10, 2014, 3 pages (Official Copy only). |
| Office Action received for Japanese Patent Application No. 2011-537745, dated Apr. 15, 2014, 4 pages (2 pages of English Translation and 2 pages of Official Copy). |
| Office Action received for Japanese Patent Application No. 2011-537745, dated Dec. 6, 2013, 7 pages (4 pages of English Translation and 3 pages of Official Copy). |
| Notice of Allowance received for Japanese Patent Application No. 2012-229673, dated Dec. 16, 2014, 3 pages (Official Copy only). |
| Office Action received for Japanese Patent Application No. 2012-229673, dated May 30, 2014, 4 pages (2 pages of English Translation and 2 pages of Official Copy). |
| Office Action received for Japanese Patent Application No. 2012-229674, dated Nov. 20, 2013, 2 pages (Official Copy only). |
| Office Action received for Japanese Patent Application No. 2012-229674, dated Nov. 27, 2014, 2 pages (Official Copy only). |
| Non-Final Office Action received from U.S. Appl. No. 13/221,734, dated Mar. 27, 2017, 9 pages. |
| Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery. |
| Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
| James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
| John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 198, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
| S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
| George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
| Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
| International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
| PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
| PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
| PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
| PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
| Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
| Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
| Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
| Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
| Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
| Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
| Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
| Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
| Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
| Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
| Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
| Arnljots, Bjöm et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
| Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
| Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
| N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (certified translation). |
| K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
| G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
| F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
| A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
| M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
| D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
| M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
| C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,”Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
| Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
| V.A. Solovev et al., Guidelines, the Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
| V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in Il All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov Il”). |
| V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
| V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
| Partial ISR for corresponding PCT/US2017/018129, dated May 15, 2017. |
| Number | Date | Country | |
|---|---|---|---|
| 20090012482 A1 | Jan 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60973086 | Sep 2007 | US | |
| 60906721 | Mar 2007 | US |
